All In Biotech

Drug Trial Radar · NCT07100106

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After a CDK4/6 Inhibitor

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 285 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

285

Planned (sponsor's estimate)

Start

Oct 7, 2025

Primary completion

Aug 31, 2028

Study completion Aug 31, 2028

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Roche (China) Holding Ltd.
First posted
Aug 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: Phase Ib and Phase II. Phase Ib will evaluate the safety and pharmacokinetics (PK) of GDC-4198 alone and in combination with giredestrant. Phase II stage will compare the activity and safety of GDC-4198 and giredestrant with abemaciclib and giredestrant. Participants from Study RGT-419B\_01-101 (NCT05304962) who are experiencing clinical benefit with GDC-4198, as determined by the investigator, may enroll in this study and continue receiving GDC-4198 at their current dose level following closure of Study RGT-419B\_01-101.

Conditions

  • Breast Cancer

Interventions

  • GDC-4198Drug

    GDC-4198 will be administered orally.

  • GiredestrantDrug

    Giredestrant will be administered orally.

  • AbemaciclibDrug

    Abemaciclib will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Incidence and Severity of Adverse Events (AEs)Time frame: Up to 36 months
  2. Phase Ib: Number of Participants With Dose-Limiting Toxicity (DLTs)Time frame: From Day 1 to Day 28 of Cycle 1 (1 cycle=28 days)
  3. Phase II: Progression-free Survival (PFS)Time frame: Up to 36 months

Locations

77 sites in 10 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute - Huntsville

    Huntsville, Alabama · Recruiting

  • University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • City of Hope - Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • University of California San Diego Medical Center

    San Diego, California · Recruiting

  • UCSF Helen Diller Family CCC

    San Francisco, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • City of Hope® Cancer Center Chicago

    Zion, Illinois · Recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Maine · Recruiting

  • Maryland Oncology Hematology - Annapolis

    Annapolis, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Washington University Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • New York Cancer & Blood Specialists

    East Patchogue, New York · Recruiting

  • Montefiore Einstein Cancer Center

    The Bronx, New York · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Novant Health Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Novant Health Oncology Specialists

    Winston-Salem, North Carolina · Recruiting

  • Cleveland Clinic Mercy Hospital

    Canton, Ohio · Recruiting

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio · Recruiting

  • Oncology Associates of Oregon, P.C

    Eugene, Oregon · Recruiting

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • University of Pennsylvania - Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • UPMC - Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Tennesse Oncology - Mt. Juliet Clinic

    Mount Juliet, Tennessee · Recruiting

  • Vanderbilt Breast Center at One Hundred Oaks

    Nashville, Tennessee · Recruiting

  • Texas Oncology (Worth) - USOR

    Dallas, Texas · Recruiting

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Virginia Oncology Associates (Norfolk) - USOR

    Norfolk, Virginia · Recruiting

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia · Recruiting

  • Cancer Research SA

    Adelaide, South Australia, Australia · Recruiting

  • Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira - ICESP

    São Paulo, Brazil · Recruiting

  • Beneficencia Portuguesa de Sao Paulo

    São Paulo, Brazil · Recruiting

  • Hospital do Cancer de Pernambuco - HCP

    Recife, Pernambuco, Brazil · Recruiting

  • ONCOSITE Centro de Pesquisa Clínica Em Oncologia

    Ijuí, Rio Grande do Sul, Brazil · Recruiting

  • Irmandade Da Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.